                         SEQUENCE LISTING

<110>  The Arizona Board of Regents on Behalf of the University of
        Arizona
       Hruby, Victor J.
       Cai, Minying
 
<120>   COMPOSITIONS AND METHODS FOR TREATING CENTRAL NERVOUS SYSTEM 
       (CNS) DISORDERS AND MOOD DISORDERS

<130>  UNIA 15.38 PCT

<150>  US 14/943,606
<151>  2015-11-17

<150>  US 62/242,874
<151>  2015-10-16

<150>  US 14/943,885
<151>  2015-11-17

<150>  US 62/242,907
<151>  2015-10-16

<150>  US 14/943,936
<151>  2015-11-17

<150>  US 62/242,850
<151>  2015-10-16

<160>  8     

<170>  PatentIn version 3.5

<210>  1
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic melanocortin 5 receptor (MC5R) peptide ligand (SEQ. No.
       1)


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  N-terminal modification is Acetyl, glycosylated amino 
       acid,-CO-(CH2)nCH3, or -CO-(CH2)nCF3, wherein n ranges from 1 to 
       6.

<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Norleucine

<220>
<221>  MOD_RES
<222>  (1)..(7)
<223>  Amino acid may be glycosylated or comprise a halogen or 
       di-halogen substitution in the side-chain.

<220>
<221>  MISC_FEATURE
<222>  (2)..(7)
<223>  Cyclization

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa is Asp, Glu, Abu, a natural amino acid or an unnatural amino 
       acid.

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Xaa is His, Pro, Oic, Ioc, Tic, Cpe, Che, Aic, Acpc, a natural 
       amino acid or an unnatural amino acid.

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Nal(2')

<220>
<221>  MOD_RES
<222>  (4)..(4)
<223>  N-methylated

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Xaa is Lys, Orn, Dab, a natural amino acid, or an unnatural amino
       acid.

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  N-methylated

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  C-terminal modification is an amide, -COOH, or -CH2OH.

<400>  1

Xaa Xaa Xaa Xaa Arg Trp Xaa 
1               5           


<210>  2
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic MC5R peptide ligand (SEQ. NO. 2)


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Norleucine

<220>
<221>  MISC_FEATURE
<222>  (2)..(7)
<223>  Cyclization

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  1-aminocyclopropane carboxylic acid (Acpc)

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Nal(2')

<220>
<221>  MOD_RES
<222>  (4)..(4)
<223>  N-methylated

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  N-methylated

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  2

Xaa Asp Xaa Xaa Arg Trp Lys 
1               5           


<210>  3
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic MC5R peptide ligand (SEQ. NO. 9)


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Norleucine

<220>
<221>  MISC_FEATURE
<222>  (2)..(7)
<223>  Cyclization

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Nal(2')

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  N-methylated

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  3

Xaa Asp His Xaa Arg Trp Lys 
1               5           


<210>  4
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic MC5R peptide ligand (SEQ. NO. 45)


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  N-terminal modification is Acetyl, glycosylated amino 
       acid,-CO-(CH2)nCH3, or -CO-(CH2)nCF3, wherein n ranges from 1 to 
       6.

<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Norleucine

<220>
<221>  MISC_FEATURE
<222>  (2)..(7)
<223>  Cyclization

<220>
<221>  MOD_RES
<222>  (4)..(4)
<223>  N-methylated

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  N-methylated

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  C-terminal modification is an amide, -COOH, or -CH2OH

<400>  4

Xaa Glu His Xaa Arg Trp Lys 
1               5           


<210>  5
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic MC5R peptide ligand (SEQ. NO. 64)


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  N-terminal modification is Acetyl, glycosylated amino 
       acid,-CO-(CH2)nCH3, or -CO-(CH2)nCF3, wherein n ranges from 1 to 
       6.

<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Norleucine

<220>
<221>  MISC_FEATURE
<222>  (2)..(7)
<223>  Cyclization

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Nal(2')

<220>
<221>  MOD_RES
<222>  (4)..(4)
<223>  N-methylated

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  diaminobutyric acid (Dab)

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  N-methylated

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  C-terminal modification is an amide, -COOH, or -CH2OH.

<400>  5

Xaa Glu Pro Xaa Arg Trp Xaa 
1               5           


<210>  6
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic MC5R peptide ligand (SEQ. NO. 87)


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  N-terminal modification is Acetyl, glycosylated amino 
       acid,-CO-(CH2)nCH3, or -CO-(CH2)nCF3, wherein n ranges from 1 to 
       6.

<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Norleucine

<220>
<221>  MISC_FEATURE
<222>  (2)..(7)
<223>  Cyclization

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  2-aminobutyric acid (Abu)

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  tetrahydro-isoquinoline-3-carboxylic Acid (Tic)

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Nal(2')

<220>
<221>  MOD_RES
<222>  (4)..(4)
<223>  N-methylated

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  diaminobutyric acid (Dab)

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  N-methylated

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  C-terminal modification is an amide, -COOH, or -CH2OH.

<400>  6

Xaa Xaa Xaa Xaa Arg Trp Xaa 
1               5           


<210>  7
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic MC5R peptide ligand (SEQ. NO. 93)


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  N-terminal modification is -CO-(CH2)CH3

<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Norleucine

<220>
<221>  MISC_FEATURE
<222>  (2)..(7)
<223>  Cyclization

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  2-aminoindane-2-carboxylic acid (Aic)

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Nal(2')

<220>
<221>  MOD_RES
<222>  (4)..(4)
<223>  N-methylated

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  ornithine (Orn)

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  N-methylated

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  7

Xaa Glu Xaa Xaa Arg Trp Xaa 
1               5           


<210>  8
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic MC5R peptide ligand (SEQ. NO. 106)


<220>
<221>  CARBOHYD
<222>  (1)..(1)
<223>  Serine having O-linked glucose

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Norleucine

<220>
<221>  MISC_FEATURE
<222>  (3)..(8)
<223>  Cyclization

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  indoline-2-carboxylic acid (Ioc)

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  D-Nal(2')

<220>
<221>  MOD_RES
<222>  (5)..(5)
<223>  N-methylated

<220>
<221>  MOD_RES
<222>  (8)..(8)
<223>  N-methylated

<400>  8

Ser Xaa Glu Xaa Xaa Arg Trp Lys 
1               5               


